tildrakizumab

08/01/2022 - "The fast improvement of the nail psoriasis in the 8 patients was unexpected, considering the fact that Tildrakizumab is a molecule that in RCTs (reSURFACE-1 and 2) studies has proved to be efficacious against plaque psoriasis but not strikingly fast, requiring at least 20 weeks to achieve the best PASI-improvements in most patients. "
12/01/2022 - "Our analysis showed tildrakizumab as a generally safe option for the treatment of psoriasis, with most of the reported adverse events being classified as mild or moderate, and rarely requiring treatment discontinuation. "
01/01/2023 - "Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in 'real-life' clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52."
01/01/2023 - "Our data confirm tildrakizumab as an effective and generally safe treatment for the management of moderate-to-severe psoriasis, with high rates of both PASI90 and PASI100 responses, and very few reported adverse events, up to 52 weeks of follow-up."
08/01/2021 - "We report 2 cases of treatment resistant nail psoriasis which showed marked improvement with the use of off-label tildrakizumab. "

01/01/2021 - "Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study."
03/01/2023 - "we assessed a good performance of tildrakizumab in patients with multiple comorbidities, multi-failure, elderly patients, and in subjects with psoriatic arthritis."
03/01/2023 - "PASI score reduced from 12.28 to 4.65 by week 12, followed by a further decrease to 1.18 at week 36 Multiple logistic regression showed that smoking, BMI ≥30, ≥3 comorbidities, previous systemic traditional or biologic drugs, psoriatic arthritis nor difficult-to-treat areas influenced the reduction of PASI and NAPSI scores during treatment with tildrakizumab (P > .05). "
01/01/2023 - "The optimal use of tildrakizumab in the elderly via improvement of Treg function and its preventive effect of psoriatic arthritis."
05/01/2022 - "Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis."

01/01/2021 - "Tildrakizumab treatment significantly improved joint and skin manifestations of PsA other than dactylitis and enthesitis. "
01/01/2019 - "Tildrakizumab has been shown in large randomized controlled trials to be effective in improving skin manifestations as well as enhancing quality of life outcomes in patients with psoriasis. "

05/01/2021 - "Disease remission of refractory vulvovaginal and gingival lichen planus with tildrakizumab."
05/01/2022 - "Successful treatment of vulvovaginal lichen planus with tildrakizumab: A case series of 24 patients."
08/01/2020 - "Successful treatment of recalcitrant lichen planus pemphigoides with tildrakizumab."
01/01/2020 - "Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab."
01/01/2020 - "We report a case of recalcitrant lichen planopilaris and frontal fibrosing alopecia demonstrating significant clinical improvement after four doses of the interleukin-23 monoclonal antibody tildrakizumab."

02/01/2021 - "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)."
08/01/2020 - "The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)."
01/01/2020 - "Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)."
10/01/2022 - "Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2."
03/01/2022 - "The safety and the efficacy of tildrakizumab has also been confirmed in special populations such as those with inflammatory bowel disease, cardiovascular disease, metabolic syndrome, and advanced age. "